NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council<
08 Apr 2025

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

Funding to support commercialization of its groundbreaking bioresorbable vascular conduits
Anaconda Biomed Enrolls First U.S. Patient in the ATHENA Clinical Trial Evaluating ANA Funnel Catheter for Ischemic Stroke Treatment<
04 Apr 2025

Anaconda Biomed Enrolls First U.S. Patient in the ATHENA Clinical Trial Evaluating ANA Funnel Catheter for Ischemic Stroke Treatment

Anaconda Biomed intends to complete enrollment in the ATHENA IDE study in the first half of 2026.
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline<
04 Apr 2025

Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline

Ysios Capital joins Neurona's 102M USD financing round
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors<
02 Apr 2025

Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

Seasoned leader whose extensive operational and commercial experience will be instrumental

CorWave Announces the Appointment of Dawn Sadlowski-Buisserez as Vice President of Operations to Support the Ramp-Up of Production<
02 Apr 2025

CorWave Announces the Appointment of Dawn Sadlowski-Buisserez as Vice President of Operations to Support the Ramp-Up of Production

Dawn Sadlowski-Buisserez brings extensive experience in implantable medical devices to support CorWave's production scale-up
Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team<
01 Apr 2025

Adcendo ApS Announces Changes in Board of Directors and Strengthens Executive Leadership Team

Company expands global footprint by establishing U.S. operation
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)<
29 Mar 2025

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

Data from Advance-HTN support the potential of lorundrostat as a best-in-class treatment for high-risk patients with uncontrolled or resistant hypertension
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update<
28 Mar 2025

LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Johnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024
Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights<
25 Mar 2025

Aura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Cash Position Expected to Support Operations into 2H 2026
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET<
25 Mar 2025

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.